Protein tyrosine kinase inhibitors as potential immunosuppressive agents
نویسندگان
چکیده
منابع مشابه
ErbB receptor tyrosine kinase inhibitors as therapeutic agents.
The ErbB family of receptor tyrosine kinases comprise four members: EGFR, ErbB2, ErbB3 and ErbB4. All are essential for normal development and participate in the functioning of normal cells. ErbB receptors, particularly EGFR and ErbB2 are commonly deregulated in certain prevalent forms of human cancer. Recently a number of small molecule inhibitors of the tyrosine kinase activity of these recep...
متن کاملMyeloproliferative Neoplasms Associated with Mutation in JAK2V617F and Tyrosine Kinase Inhibitors as Therapeutic Strategy
MPNs including a heterogeneous group of clonal or oligoclonal hamtopathies characterized by proliferation and accumulation of mature myeloid cells. JAK2 tyrosine kinase mutation is the most common molecular lesion identified in 90% of cases. JAK2 is involved in EPO signaling pathway, and mutations in it lead to EPO-independent spontaneous phosphorylation. Most tyrosine kinase inhibitors (TKI) a...
متن کاملIdentification of potential inhibitors based on compound proposal contest: Tyrosine-protein kinase Yes as a target
A search of broader range of chemical space is important for drug discovery. Different methods of computer-aided drug discovery (CADD) are known to propose compounds in different chemical spaces as hit molecules for the same target protein. This study aimed at using multiple CADD methods through open innovation to achieve a level of hit molecule diversity that is not achievable with any particu...
متن کاملPotential of Small Molecule Protein Tyrosine Kinase Inhibitors as Immunomodulators and Inhibitors of the Development of Diabetes
1 Diabetes and Cell Biology Laboratory, BakerIDI Heart and Diabetes Institute, Melbourne, VIC, 3004, Australia; 2 Medicine and Immunology Departments, Central and Eastern Clinical School, Alfred Hospital, Monash University, Melbourne, VIC, 3004, Australia; 3 Clinical Services Division, BakerIDI Heart and Diabetes Institute, Melbourne, VIC, 3004, Australia; 4 Centre for Diabetes Research, Wester...
متن کاملRecent developments of protein kinase inhibitors as potential AD therapeutics
Present Alzheimer's disease (AD) therapies suffer from inefficient effects on AD symptoms like memory or cognition, especially in later states of the disease. Used acteylcholine esterase inhibitors or the NMDA receptor antagonist memantine address one target structure which is involved in a complex, multifactorial disease progression. So the benefit for patients is presently poor. A more close ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Japanese Journal of Pharmacology
سال: 1995
ISSN: 0021-5198
DOI: 10.1016/s0021-5198(19)46298-7